Latest
Tuesday, November 17, 2026
  • New YorkNY
  • LondonLDN
  • TokyoTYO
Business

Altria Group's CEO Discusses Challenges in Nicotine Business

Altria's On! nicotine pouch brand is struggling to compete with Philip Morris's Zyn due to regulatory hurdles and a misconception about nicotine's harm.

Altria CEO says ‘responsibility needs to be at the heart’ of its FDA-regulated nicotine business. It’s part of why it sued the regulator
Source: Fortune

Altria Group's CEO Sal Mancuso emphasized the importance of responsibility in the company's FDA-regulated nicotine business during a recent forum in Detroit.

The shift towards less harmful nicotine alternatives by Big Tobacco companies has created new challenges for their relationships with regulators, particularly when it comes to competing with other businesses in the space. Altria's On! nicotine pouch brand is a key innovation for the company, but regulations have slowed growth, making it harder for the company to compete.

The Marlboro-maker announced its Moving Beyond Smoking initiative last year as consumers increasingly turn away from cigarettes and towards smoke-free alternatives like NJOY vapes and On! nicotine pouches. Altria's focus on these products has led to a renewed emphasis on competing with Philip Morris's Zyn in the market.

Altria's CEO Sal Mancuso acknowledged that the company is currently at a disadvantage in the pouch category, but expressed confidence in its ability to lead the way over time. According to Mancuso, one of the main obstacles facing the industry is the widespread misconception that nicotine itself causes harm from tobacco use.

Mancuso also highlighted the challenges posed by FDA regulations on his company's business, stating that responsibility must be at the forefront of everything Altria does in the nicotine sector. This emphasis on responsibility reflects the changing landscape of the tobacco industry and its growing focus on smoke-free products.

Altria's lawsuit against the FDA is centered on the regulatory agency's review process for new tobacco products. The company claims that this process has become a major hurdle in getting its newer nicotine products to market. Specifically, Altria alleges that the FDA's evaluation of these products takes significantly longer than the 180-day deadline set by law.

The Premarket Tobacco Product Application (PMTA) review process is a key point of contention between Altria and the FDA. Under this process, new tobacco products must undergo a thorough examination to determine whether they provide an overall public health benefit. However, Altria argues that the FDA's bureaucratic red tape has led to excessively long delays in reviewing these applications.

Meanwhile, foreign competitors are flooding store shelves with their own nicotine products, often mislabeled as being made in the US. This not only erodes market share for legitimate companies but also allows illicit products to circumvent safety standards set by the FDA. Altria claims that this is a major concern and that enforcement against these illegal products is urgently needed.

The issue of labeling is particularly problematic, with overseas products being marketed as made in the US when they are actually imported from countries like China. This misrepresentation can lead consumers to believe that these products meet stricter safety standards than they actually do. The FDA's failure to address this issue has created a regulatory vacuum that Altria is seeking to fill through its lawsuit.

As part of its efforts to overhaul the PMTA review process, Altria is pushing for revisions to be made by the FDA. This includes streamlining the application process and reducing the time it takes for products to reach market. By doing so, Altria hopes to create a more level playing field for legitimate companies and reduce the proliferation of illicit nicotine products.

The regulatory framework governing nicotine products is in dire need of reform, according to Altria's CEO, who believes that excessive information and lack of durability in guidelines hinder legitimate businesses from operating effectively.

A more streamlined approach to regulation would allow companies like Altria to focus on delivering high-quality products while providing consumers with a wider range of choices. Rapid authorization processes would enable consumers to access various nicotine products without unnecessary delays or uncertainty.

The regulatory landscape for cannabis in the US, where half of states have legalized it but lack federal standards, serves as a relevant example. This "hodgepodge" of regulations creates an uneven playing field that favors illicit operators over responsible businesses like Altria.

Facts based on reporting originally published by Fortune.

You may republish this story, in full or in part, if you credit News Central Site and link to it (licence CC BY 4.0). Photos are not included.